| 2022-11 |
Selective and antagonist-dependent µ-opioid receptor activation by the combination of 2-{[2-(6-chloro-3,4-dihydro-1(2H)-quinolinyl)-2-oxoethyl]sulfanyl}-5-phenyl-4,6-(1H,5H)-pyrimidinedione and naloxone/naltrexone |
Bioorganic Chemistry. 2022 Nov;128:Article number 105905. |
 |
| 2021-08-01 |
DBPR108, a novel dipeptidyl peptidase-4 inhibitor with antihyperglycemic activity |
Life Sciences. 2021 Aug 1;278:Article number 119574. |
|
| 2021-01 |
BPRDP056, a novel small molecule drug conjugate specifically targeting phosphatidylserine for cancer therapy |
Translational Oncology. 2021 Jan;14(1):Article number 100897. |
|
| 2019-07 |
BPRDP056, a novel small molecule drug conjugate specifically targeting phosphatidylserine for cancer therapy |
Cancer Research. 2019 Jul;79(13, Suppl.):Abstract number 227. |
|
| 2019-04-01 |
A novel, potent, and orally bioavailable thiazole HCV NS5A inhibitor for the treatment of hepatitis C virus |
European Journal of Medicinal Chemistry. 2019 Apr 1;167:245-268. |
|
| 2019-04-01 |
The in vivo antinociceptive and mu-opioid receptor activating effects of the combination of N-phenyl-2′,4′-dimethyl-4,5′-bi-1,3-thiazol-2-amines and naloxone |
European Journal of Medicinal Chemistry. 2019 Apr 1;167:312-323. |
|
| 2019-03 |
Synthesis and biological evaluation of N-glucosyl indole derivatives as sodium-dependent glucose co-transporter 2 inhibitors |
Bioorganic Chemistry. 2019 Mar;83:520-525. |
|
| 2018-04 |
4-Bromophenylhydrazinyl benzenesulfonylphenylureas as indoleamine 2,3-dioxygenase inhibitors with in vivo target inhibition and anti-tumor efficacy |
Bioorganic Chemistry. 2018 Apr;77:600-607. |
|
| 2018-01-01 |
Identification of an oxime-containing C-glucosylarene as a potential inhibitor of sodium-dependent glucose co-transporter 2 |
European Journal of Medicinal Chemistry. 2018 Jan 1;143:611-620. |
|
| 2017-06-22 |
Targeting coronaviral replication and cellular JAK2 mediated dominant NF-kappaB activation for comprehensive and ultimate inhibition of coronaviral activity |
Scientific Reports. 2017 Jun 22;7:Article number 4105. |
|
| 2017-01 |
A potent, selective, and orally bioavailable HCV NS5A inhibitor for treatment of Hepatitis C Virus: (S)-1-((R)-2-(Cyclopropanecarboxamido)-2-phenylacetyl)-N-(4-phenylthiazo l-2-yl)pyrrolidine-2-carboxamide |
Journal of Medicinal Chemistry. 2017 Jan;60(1):228-247. |
|
| 2016-05 |
N-Indolylglycosides bearing modifications at the glucose C6-Position as Sodium-Dependent Glucose Co-transporter 2 inhibitors |
Bioorganic and Medicinal Chemistry. 2016 May;24(10):2242-2250. |
|
| 2016-01 |
Phenyl benzenesulfonylhydrazides exhibit selective Indoleamine 2,3-Dioxygenase inhibition with potent in vivo pharmacodynamic activity and antitumor efficacy |
Journal of Medicinal Chemistry. 2016 Jan;59(1):419-430. |
|
| 2015-07-31 |
作為極光激酶抑制劑的稠合雙環嘧啶化合物 |
HK1151694/2015-07-31 |
|
| 2015-07-29 |
脯氨酸衍生物 |
ZL201080002506.6/2015-07-29 |
|
| 2015-07-22 |
作为酪胺酸激酶抑制剂的稠合双环及多环嘧啶化合物 |
ZL200980144458.1/2015-07-22 |
|
| 2015-07 |
Development and application of a fluorescent glucose uptake assay for the high-throughput screening of non-glycoside SGLT2 inhibitors |
European Journal of Pharmaceutical Sciences. 2015 Jul;74:40-44. |
|
| 2015-07 |
Pharmacological induction of human fetal globin gene in hydroxyurea-resistant primary adult erythroid cells |
Molecular and Cellular Biology. 2015 Jul;35(14):2541-2553. |
|
| 2015-07 |
Identification of a potent 5-phenyl-thiazol-2-ylamine-based inhibitor of FLT3 with activity against drug resistance-conferring point mutations |
European Journal of Medicinal Chemistry. 2015 Jul;100:151-161. |
|
| 2015-06-01 |
治療C型肝炎病毒感染之醫藥組成物 |
I486160/2015-06-01 |
|
| 2015-05-29 |
Proline derivatives |
JP5753185/2015-05-29 |
|
| 2015-05 |
A novel peripheral cannabinoid receptor 1 antagonist, BPR0912, reduces weight independently of food intake and modulates thermogenesis |
Diabetes, Obesity and Metabolism. 2015 May;17(5):495-504. |
|
| 2015-04-14 |
Fused multicyclic compounds as protein kinase inhibitors |
US9006252B2/2015-04-14 |
|
| 2015-02-24 |
Pyrazole compounds |
US8962845/2015-02-24 |
|
| 2015-02-11 |
吡唑類化合物 |
I472514/2015-02-11 |
|
| 2014-12-01 |
Morphine drives internal ribosome entry site-mediated hnRNP K translation in neurons through opioid receptor-dependent signaling |
Nucleic Acids Research. 2014 Dec 1;42(21):13012-13025. |
|
| 2014-11-19 |
咪唑-4-酮及咪唑-4-硫酮化合物 |
ZL200910006503.9/2014-11-19 |
|
| 2014-10-29 |
作為極光激酶抑制劑的稠合雙環嘧啶化合物 |
ZL200980115577.4/2014-10-29 |
|
| 2014-10-21 |
化合物於製造治療病毒感染的藥物之用途 |
I457121/2014-10-21 |
|
| 2014-09-01 |
治療阿茲海默症或帕金森氏症之醫藥組成物 |
I450716/2014-09-01 |
|
| 2014-09 |
Discovery, structure-activity relationship studies, and anti-nociceptive effects of 1-phenyl-3,6,6-trimethyl-1,5,6,7-tetrahydro-4H-indazol-4-one as novel opioid receptor agonists |
Bioorganic and Medicinal Chemistry. 2014 Sep;22(17): 4694-4703. |
|
| 2014-08-15 |
Anticancer oral formulation |
特許第5596680號/2014-08-15 |
|
| 2014-08-01 |
Pyrrolidine derivatives |
特許第5,586,484號/2014-08-01 |
|
| 2014-08 |
Discovery and structure-activity relationships of phenyl benzenesulfonylhydrazides as novel indoleamine 2,3-dioxygenase inhibitors |
Bioorganic and Medicinal Chemistry Letters. 2014 Aug;24(15):3403-3406. |
|
| 2014-08 |
Discovery of selective inhibitors of Glutaminase-2, which inhibit mTORC1, activate autophagy and inhibit proliferation in cancer cells |
Oncotarget. 2014 Aug;5(15):6087-6101. |
|
| 2014-07-30 |
Pyrazole compounds |
ZA201303800B/2014-07-30 |
|
| 2014-06-04 |
抗癌口服制剂 |
ZL200980126979.4/2014-06-04 |
|
| 2014-05-12 |
Pyrrolidine derivatives |
J001349/2014-05-12 |
|
| 2014-05-11 |
二苯並〔f,h〕異喹啉衍生物及其醫藥組成物 |
I436983/2014-05-11 |
|
| 2014-05-08 |
Pyrrolidine derivatives |
AU2009222198/2014-05-08 |
|
| 2014-04-29 |
Quinoline compounds and their use for treating viral infection |
US8710079B2/2014-04-29 |
|
| 2014-04-25 |
Pyrrolidine derivatives |
HK1149261/2014-04-25 |
|
| 2014-04-21 |
咪唑-4-酮及咪唑-4-硫酮化合物 |
I434686/2014-04-21 |
|
| 2014-04-21 |
作為蛋白質激酶抑制劑之吡唑化合物及噻唑化合物、其醫藥組成物及用途 |
I434834/2014-04-21 |
|
| 2014-04-15 |
Glycoside compounds |
US8697658B2/2014-04-15 |
|
| 2014-03-20 |
Fused bicyclic pyrimidine compounds as aurora kinase inhibitors |
JP5502072/2014-03-20 |
|
| 2014-03-11 |
脯胺酸衍生物 |
I429645/2014-03-11 |
|
| 2014-02-19 |
Pyrrolidine derivatives |
EP2252582/2014-02-19 |
|
| 2014-01-08 |
Evaluation of the antitumor effects of BPR1J-340, a potent and selective FLT3 inhibitor, alone or in combination with an HDAC inhibitor, vorinostat, in AML cancer |
PLoS ONE. 2014 Jan 8;9(1):Article number e83160. |
|
| 2013-12-18 |
吡咯烷化合物 |
ZL200980107941.2/2013-12-18 |
|
